Cannabis in Movement Disorders

Abstract

Central cannabinoid receptors are densely located in the output nuclei of the basal ganglia (globus pallidus, substantia nigra pars reticulata), suggesting their involvement in the regulation of motor activity. Furthermore, there is evidence that endogenous cannabinoid transmission plays a role in the manipulation of other transmitter systems within the basal ganglia by increasing GABAergic transmission, inhibiting glutamate release and affecting dopaminergic uptake. Most hyperkinetic and hypokinetic movement disorders are caused by a dysfunction of basal ganglia-thalamo-cortical loops. It has been suggested that an endogenous cannabinoid tone participates in the control of movements and, therefore, the central cannabinoid system might play a role in the pathophysiology of these diseases. During the last years in humans a limited number of clinical trials demonstrated that cannabinoids might be useful in the treatment of movement disorders. Despite the lack of controlled studies there is evidence that cannabinoids are of therapeutic value in the treatment of tics in Tourette syndrome, the reduction of levodopa-induced dyskinesia in Parkinson''s disease and some forms of tremor and dystonia. It can be speculated that cannabinoid antagonists might be useful in the treatment of chorea in Huntington''s disease and hypokinetic parkinsonian syndromes.

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease

“…Despite a lack of clinical evidence, patients suffering from HD may be seeking medical marijuana or acquiring it from other sources in an attempt to relieve some of the symptoms of their disease (Müller-Vahl et al, 1999;Meisel and Friedman, 2012;Koppel et al, 2014). Most medically available and tested illicit marijuana contains a high concentration of THC relative to other cannabinoids, such as CBD (De Backer et al, 2012).…”

Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor

“…Recently interest in their therapeutic value has been fuelled by suggestions to apply these drugs in cancer treatment to improve analgesia and to relieve insomnia (1). Because of their neuroprotective properties, cannabinoids have also been proposed to be useful drugs for the therapy of neurodegenerative diseases like Parkinson's disease, Huntington disease, and multiple sclerosis (2). Orally applicable ⌬ 9 -tetrahydrocannabinol (THC; Dronabinol, Marinol) and its synthetic derivative Nabilone (Cesamet) have been approved by the United States Food and Drug Administration to stimulate the appetite of patients with AIDS and to reduce the nausea of cancer patients undergoing chemotherapy (1,3,4).…”

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

“…However, cannabinoid agonists are unlikely to be used for reducing bradykinesia in PD because of their hypokinetic profile both in primates and humans (Consroe, 1998;Mü ller-Vahl et al, 1999a;Romero et al, 2002;Brotchie, 2003;Croxford, 2003;Croxford and Miller, 2003).…”